老年人黑色素瘤诊断中免疫组化应用趋势
结果显示,诊断时或前后使用免疫组化的比例从2000年的11%升至2017年的51%,各分期及所有登记处均增加但速率不同。
要点
- 2000至2017年间,黑色素瘤诊断伴随免疫组化声明的比例从11%升至51%。
- 免疫组化使用增加见于所有分期,包括原位黑色素瘤。
- 2017年各SEER登记处免疫组化使用率差异较大,范围为39%至68%。
核心结论
- 病理医生在黑色素瘤诊断中使用免疫组化的比例显著上升且存在登记处间差异,需进一步研究其临床效用。
主要发现
- 2000年11%的黑色素瘤病例在诊断时或附近有免疫组化声明,该比例逐年增加,2017年达51%。
- 免疫组化使用增加见于所有分期,包括原位黑色素瘤;17个SEER登记处均有增加但速率不同,2017年使用率范围为39%至68%。
临床怎么用
- 临床医生应了解免疫组化在黑色素瘤诊断中应用日益普遍,但需结合临床判断其必要性。
局限性
- 研究为回顾性设计,基于索赔数据,可能无法完全反映实际临床病理实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pathologic assessment to diagnose skin biopsies, especially for cutaneous melanoma, can be challenging, and immunohistochemistry (IHC) staining has the potential to aid decision-making. Currently, the temporal trends regarding the use of IHC for the examination of skin biopsies on a national level have not been described. OBJECTIVE: To illustrate trends in the use of IHC for the examination of skin biopsies in melanoma diagnoses. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cross-sectional study was conducted to examine incident cases of melanoma diagnosed between January 2000 and December 2017. The analysis used the SEER-Medicare linked database, incorporating data from 17 population-based registries. The study focused on incident cases of in situ or malignant melanoma of the skin diagnosed in patients 65 years or older. Data were analyzed between August 2022 and November 2023. MAIN OUTCOMES AND MEASURES: The main outcomes encompassed the identification of claims for IHC within the month of melanoma diagnoses and extending up to 14 days into the month following diagnosis. The SEER data on patients with melanoma comprised demographic, tumor, and area-level characteristics. RESULTS: The final sample comprised 132 547 melanoma tumors in 116 117 distinct patients. Of the 132 547 melanoma diagnoses meeting inclusion criteria from 2000 to 2017, 43 396 cases had accompanying IHC claims (33%). Among these cases, 28 298 (65%) were diagnosed in male patients, 19 019 (44%) were diagnosed in patients aged 65 years to 74 years, 16 444 (38%) in patients aged 75 years to 84 years, and 7933 (18%) in patients aged 85 years and older. In 2000, 11% of melanoma cases had claims for IHC at or near the time of diagnosis. This proportion increased yearly, with 51% of melanoma cases having associated IHC claims in 2017. Increasing IHC use is observed for all stages of melanoma, including in situ melanoma. Claims for IHC in melanomas increased in all 17 SEER registries but at different rates. In 2017, the use of IHC for melanoma diagnosis ranged from 39% to 68% across registries. CONCLUSIONS AND RELEVANCE: Considering the dramatically rising and variable use of IHC in diagnosing melanoma by pathologists demonstrated in this retrospective cross-sectional study, further investigation is warranted to understand the clinical utility and discern when IHC most improves diagnostic accuracy or helps patients.
引用
- Ojukwu K, Eguchi MM, Adamson AS, et al. Immunohistochemistry for Diagnosing Melanoma in Older Adults. JAMA Dermatol. 2024. PMID: 38446470. doi:10.1001/jamadermatol.2023.6417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。